Coronavirus vaccine update: COVAXIN human trials start at PGI Rohtak

Coronavirus vaccine update: COVAXIN human trials start at PGI Rohtak

Coronavirus vaccine: The human trial of COVAXIN has started in All India Institute of Medical Sciences in Patna and Post-Graduate Institute of Medical Sciences in Rohtak

Advertisement
COVAXIN, the country's first possible vaccine against COVID-19, will be tested on over 1,100 people in two phasesCOVAXIN, the country's first possible vaccine against COVID-19, will be tested on over 1,100 people in two phases
BusinessToday.In
  • Jul 17, 2020,
  • Updated Jul 17, 2020 5:33 PM IST

According to the latest update on the COVID-19 vaccine, Bharat Biotech has successfully started human trials on its vaccine candidate 'COVAXIN'.

The human trial of Bharat Biotech's anti-COVID-19 vaccine has been initiated in Rohtak's Post-Graduate Institute of Medical Sciences today, Haryana Health Minister Anil Vij tweeted.

"Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak today," said Vij.

Advertisement

"Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse effects," he said.

COVAXIN, being developed by the Hyderabad-based biotech company in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV), is India's first indigenous COVID-19 vaccine. The human trial of COVAXIN has started in All India Institute of Medical Sciences in Patna and Post-Graduate Institute of Medical Sciences in Rohtak.

 

According to the latest update on the COVID-19 vaccine, Bharat Biotech has successfully started human trials on its vaccine candidate 'COVAXIN'.

The human trial of Bharat Biotech's anti-COVID-19 vaccine has been initiated in Rohtak's Post-Graduate Institute of Medical Sciences today, Haryana Health Minister Anil Vij tweeted.

"Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak today," said Vij.

Advertisement

"Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse effects," he said.

COVAXIN, being developed by the Hyderabad-based biotech company in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV), is India's first indigenous COVID-19 vaccine. The human trial of COVAXIN has started in All India Institute of Medical Sciences in Patna and Post-Graduate Institute of Medical Sciences in Rohtak.

 

Read more!
Advertisement